Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

107 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Long-Term Outcomes of Rituximab-Treated Adult Patients with Podocytopathies.
Gauckler P, Matyjek A, Kapsia S, Marinaki S, Quintana LF, Diaz MM, King C, Griffin S, Ramachandran R, Odler B, Eller K, Artan AS, Mirioglu S, Busch M, Schaepe M, Turkmen K, Cheung CK, Pepper RJ, Juarez GF, Pascual J, Auñón P, García-Carro C, Rodriguez A, Alberici F, Luzardo L, Chebotareva N, Schönermarck U, Fernández L, Radhakrishnan J, Guaman K, Peleg Y, Hoisnard L, Audard V, Papasotiriou M, Krnanska N, Tesar V, Hruskova Z, Bruchfeld A, Stangou M, Lioulios G, Faguer S, Ribes D, Salhi S, Windpessl M, Galešić K, Crnogorac M, Zagorec N, Mayer G, Kronbichler A; RITERM Study Team. Gauckler P, et al. Among authors: schonermarck u. J Am Soc Nephrol. 2024 Oct 16. doi: 10.1681/ASN.0000000520. Online ahead of print. J Am Soc Nephrol. 2024. PMID: 39431468 No abstract available.
Rituximab in Membranous Nephropathy.
Gauckler P, Shin JI, Alberici F, Audard V, Bruchfeld A, Busch M, Cheung CK, Crnogorac M, Delbarba E, Eller K, Faguer S, Galesic K, Griffin S, van den Hoogen MWF, Hrušková Z, Jeyabalan A, Karras A, King C, Kohli HS, Mayer G, Maas R, Muto M, Moiseev S, Odler B, Pepper RJ, Quintana LF, Radhakrishnan J, Ramachandran R, Salama AD, Schönermarck U, Segelmark M, Smith L, Tesař V, Wetzels J, Willcocks L, Windpessl M, Zand L, Zonozi R, Kronbichler A; RITERM study group. Gauckler P, et al. Among authors: schonermarck u. Kidney Int Rep. 2021 Jan 13;6(4):881-893. doi: 10.1016/j.ekir.2020.12.035. eCollection 2021 Apr. Kidney Int Rep. 2021. PMID: 33912740 Free PMC article. Review.
Perspective on COVID-19 vaccination in patients with immune-mediated kidney diseases: consensus statements from the ERA-IWG and EUVAS.
Stevens KI, Frangou E, Shin JIL, Anders HJ, Bruchfeld A, Schönermarck U, Hauser T, Westman K, Fernandez-Juarez GM, Floege J, Goumenos D, Turkmen K, van Kooten C, McAdoo SP, Tesar V, Segelmark M, Geetha D, Jayne DRW, Kronbichler A; Immunonephrology Working Group (IWG) of the European Renal Association (ERA) and the European Vasculitis Society (EUVAS). Stevens KI, et al. Among authors: schonermarck u. Nephrol Dial Transplant. 2022 Jul 26;37(8):1400-1410. doi: 10.1093/ndt/gfac052. Nephrol Dial Transplant. 2022. PMID: 35244174 Free PMC article.
ANCA Vasculitis Induction Management During the COVID-19 Pandemic.
Salas A, Kant S, Floyd L, Kratky V, Brix SR, Prendecki M, Schönermarck U, Scott J, Saha M, Gauckler P, Li T, Sharma PD, Ayoub I, Morris AD, Dhaygude AP, Hruskova Z, Tesar V, McAdoo SP, Little MA, Derebail VK, Poulton CJ, Seo P, Kronbichler A, Geetha D. Salas A, et al. Among authors: schonermarck u. Kidney Int Rep. 2021 Nov;6(11):2903-2907. doi: 10.1016/j.ekir.2021.08.009. Epub 2021 Aug 19. Kidney Int Rep. 2021. PMID: 34426797 Free PMC article. No abstract available.
Screening for NPHS2 mutations may help predict FSGS recurrence after transplantation.
Jungraithmayr TC, Hofer K, Cochat P, Chernin G, Cortina G, Fargue S, Grimm P, Knueppel T, Kowarsch A, Neuhaus T, Pagel P, Pfeiffer KP, Schäfer F, Schönermarck U, Seeman T, Toenshoff B, Weber S, Winn MP, Zschocke J, Zimmerhackl LB. Jungraithmayr TC, et al. Among authors: schonermarck u. J Am Soc Nephrol. 2011 Mar;22(3):579-85. doi: 10.1681/ASN.2010010029. Epub 2011 Feb 25. J Am Soc Nephrol. 2011. PMID: 21355056 Free PMC article.
The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment.
Rondeau E, Scully M, Ariceta G, Barbour T, Cataland S, Heyne N, Miyakawa Y, Ortiz S, Swenson E, Vallee M, Yoon SS, Kavanagh D, Haller H; 311 Study Group. Rondeau E, et al. Kidney Int. 2020 Jun;97(6):1287-1296. doi: 10.1016/j.kint.2020.01.035. Epub 2020 Mar 6. Kidney Int. 2020. PMID: 32299680 Free article. Clinical Trial.
Long-Term Efficacy and Safety of the Long-Acting Complement C5 Inhibitor Ravulizumab for the Treatment of Atypical Hemolytic Uremic Syndrome in Adults.
Barbour T, Scully M, Ariceta G, Cataland S, Garlo K, Heyne N, Luque Y, Menne J, Miyakawa Y, Yoon SS, Kavanagh D; 311 Study Group Members. Barbour T, et al. Kidney Int Rep. 2021 Mar 24;6(6):1603-1613. doi: 10.1016/j.ekir.2021.03.884. eCollection 2021 Jun. Kidney Int Rep. 2021. PMID: 34169200 Free PMC article.
Kidney transplantation in ANCA-associated vasculitis.
Sagmeister MS, Grigorescu M, Schönermarck U. Sagmeister MS, et al. Among authors: schonermarck u. J Nephrol. 2019 Dec;32(6):919-926. doi: 10.1007/s40620-019-00642-x. Epub 2019 Aug 30. J Nephrol. 2019. PMID: 31471816 Review.
107 results